Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2020

View Archived Issues

CTA cleared in China to initiate phase IIa study of infigratinib in gastric cancer

Enrollment ongoing in phase III study of marzeptacog alfa

Amgen initiates phase III study of ABP-654 in moderate to severe plaque psoriasis

Braeburn receives complete response letter for Brixadi in the U.S.

First patient dosed in phase III ASPEN study of brensocatib in bronchiectasis

Cel-Sci reports preclinical data on LEAPS COV-19 peptides

Arcutis presents data from long-term safety study of ARQ-151 in plaque psoriasis

Biotest presents compositions comprising recombinant factor VIII protein

EPA/DHA does not show benefit in patients with cardiovascular risk

Royal Melbourne Institute of Technology describes new gold complexes

Bacainn completes first-in-human study BT-051

New inhibitors of autophagy identified at Deciphera Pharmaceuticals

New THR-beta agonists identified at Aligos Therapeutics

Bristol Myers Squibb patents TLR7/TLR8/TLR9 antagonists

Environmental support helps blood stem cells cope

Genethon cleared to begin clinical trial in France with GNT-0004 for Duchenne muscular dystrophy

OncoMyx presents armed Myxoma virus as potentially promising new oncolytic virotherapy

Appili initiates new phase III trial of Avigan for treatment of COVID-19

Phase III ATLANTIS results with Zepzelca and doxorubicin for SCLC

Tc24-C4.10E shows promise for the treatment of Chagas disease

CARB-X awards funding to German institutions

Galapagos begins phase II trial of CFTR inhibitor GLPG-2737 for ADPKD

reMYND initiates first-in-human trial of ReS19-T for Alzheimer's

New phase II trial evaluates LYT-100 for long COVID respiratory complications and related sequelae

FDA approves [68]Ga-PSMA-11 for PET imaging of PSMA-positive lesions in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...